Q2 EPS Forecast for Rockwell Medical Decreased by Analyst

Rockwell Medical, Inc. (NASDAQ:RMTI) – Investment analysts at HC Wainwright reduced their Q2 2026 earnings estimates for shares of Rockwell Medical in a research report issued to clients and investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.02) per share for the quarter, down from their previous forecast of ($0.01). HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.05) EPS.

Other research analysts have also recently issued research reports about the stock. Wall Street Zen upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rockwell Medical in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $2.00.

Rockwell Medical Stock Performance

NASDAQ RMTI opened at $0.89 on Wednesday. The stock has a market cap of $35.20 million, a P/E ratio of -5.95 and a beta of 1.71. The company’s 50-day simple moving average is $1.00 and its 200 day simple moving average is $1.03. Rockwell Medical has a twelve month low of $0.78 and a twelve month high of $2.10. The company has a quick ratio of 3.63, a current ratio of 3.98 and a debt-to-equity ratio of 0.25.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). The business had revenue of $18.35 million during the quarter, compared to analyst estimates of $18.58 million. Rockwell Medical had a negative net margin of 7.67% and a negative return on equity of 15.64%.

Institutional Investors Weigh In On Rockwell Medical

A number of hedge funds have recently made changes to their positions in the company. Panagora Asset Management Inc. acquired a new position in Rockwell Medical during the 2nd quarter worth about $41,000. Vanguard Group Inc. increased its position in Rockwell Medical by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock valued at $1,625,000 after acquiring an additional 148,737 shares in the last quarter. GSA Capital Partners LLP raised its stake in shares of Rockwell Medical by 635.1% in the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock worth $197,000 after acquiring an additional 141,672 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Rockwell Medical by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock worth $304,000 after acquiring an additional 41,668 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Rockwell Medical during the fourth quarter worth approximately $84,000. Institutional investors and hedge funds own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.